bluebird bio, Inc.: M&A transaction — bluebird bio sells Rare Pediatric Disease PRV to Bristol-Myers Squibb for $95M cash

bluebird bio, Inc.

Sold PRV awarded for ZYNTEGLO (betibeglogene autotemcel) for β-thalassemia to Bristol-Myers Squibb.
Total purchase price of $95 million paid in cash at closing on January 5, 2023.
Sale closed simultaneously with execution of Asset Purchase Agreement; no assumed liabilities.
Proceeds provide capital infusion; no specific use of proceeds disclosed.
PRV transfer required FDA notification within 14-30 days post-closing.

item 1.01 item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

bluebird bio, Inc. completed a disposition involving Bristol-Myers Squibb Company for $95 million (closed 2023-01-05).

Action: disposition
Counterparty: Bristol-Myers Squibb Company
Consideration: $95 million
Closing: 2023-01-05

Exact text from the filing

Pursuant to the PRV Transfer Agreement, Buyer agreed to pay the Company $95 million, payable in cash, upon the closing of the sale, which occurred simultaneously with the parties entering into the PRV Transfer Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

bluebird bio, Inc. entered into PRV Transfer Agreement with Bristol-Myers Squibb Company valued at $95 million (effective 2023-01-05).

Action: entry
Agreement: asset purchase
Counterparty: Bristol-Myers Squibb Company
Value: $95 million
Effective: 2023-01-05

Exact text from the filing

On January 5, 2023, bluebird bio, Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”) with Bristol-Myers Squibb Company (“Buyer”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to Buyer.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-23-002980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.